Q (haiku): What percentage of patients in the MSK-CHORD Study have at least one TP53 mutation? ▶ read_guide { "uri": "cbioportal://mutation-frequency-guide" } ▶ list_studies { "search": "MSK-CHORD" } ◀ result # Mutation Frequency Analysis Guide ## IMPORTANT: Reporting Mutation Frequencies - **ALWAYS report frequencies as percentages**, not raw counts: `frequency = (altered_samples / total_profiled_samples) × 100` - For quick frequency lookups, **prefer the TCGA Pan-Cancer Atlas study first**, then offer to expand to other studies - When reporting across multiple studies, show **ranges** (e.g., "TP53 is mutated in 30–60% of samples") rather than a single average - **NEVER** sum mutation events across studies to compute an aggregate frequency — this can exceed 100% due to double-counting - Warn users that samples may overlap across cohorts (e.g., MSK studies may share patients) - **Choose and state the counting unit**: use patient-level frequencies for prevalence/rate questions unless the user explicitly asks for samples; use sample-level frequencies when the user asks about samples. - **For "across cancer types" questions**, jump to the [Cross-Cancer-Type Mutation Frequency](#cross-cancer-type-mutation-frequency) section below — there is one correct recipe and several common wrong ones. ## Counting Unit: Samples vs Patients Before answering any mutation count or frequency question, decide whether the unit is samples or patients and state that choice in the answer. | User wording | Counting unit | |--------------|---------------| | "prevalence", "rate", "fraction of patients", "patients with", "how common is" | Patient-level: `COUNT(DISTINCT patient_unique_id)` | | "samples", "specimens", "biopsies", sample-level cohort composition | Sample-level: `COUNT(DISTINCT sample_unique_id)` | | Ambiguous | Ask, or default to patient-level for prevalence/rate language and say so | ### Cross-study sample-count caveat When an answer touches more than one study and reports a sample count, prepend a one-line caveat: > Sample IDs are unique within cBioPortal study prefixes, not guaranteed biological-sample identifiers across studies; overlapping cohorts can count the same patient/sample more than once. Prefer one of these safer approaches: - Use a shipped `cancer_study_query_preferences` cohort such as `pan_cancer_tcga` or `all_studies_non_redundant`. - Restrict to one named study. - Aggregate by `patient_unique_id` when the biological question is patient prevalence. ## STOP rule: a frequency above 100% means your query is wrong If your query returns a frequency over 100%, **do not try to debug or explain the data inconsistency to the user**. The cause is always one of these query bugs: - Summing mutation events instead of `COUNT(DISTINCT sample_unique_id)` for the numerator - Using a study-wide sample count as the denominator instead of the gene-specific profiled count - Cross-study aggregation where the same biological sample appears under multiple `sample_unique_id` values (e.g., MSK-IMPACT and MSK-CHORD share patients) - **Joining the profiled CTE through `gene_panel` / `gene_panel_list` without a WES branch.** `gene_panel_id = 'WES'` is *not* a row in … (35166 more chars) ◀ result {"result":[{"cancer_study_identifier":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","type_of_cancer_id":"mixed","sample_count":25040,"has_guide":true,"url":"https://www.cbioportal.org/study/summary?id=msk_chord_2024"}]} ▶ get_study_guide { "study_id": "msk_chord_2024" } ▶ clickhouse_list_table_columns { "table": "gene_mutation_frequency_in_study" } ◀ result # MSK-CHORD (MSK, Nature 2024) **Study ID:** `msk_chord_2024` ## Overview Targeted sequencing via MSK-IMPACT panels. Clinical annotations include some derived from natural language processing (denoted NLP). **Exactly five cancer types** (`CANCER_TYPE`, patients): Non-Small Cell Lung Cancer 7,809, Colorectal Cancer 5,543, Breast Cancer 5,368, Prostate Cancer 3,211, Pancreatic Cancer 3,109. There is **no melanoma** or any other cancer type; say so up front if asked, instead of substituting another type. **No therapy-response variable.** There is no RECIST, objective response, or best-response attribute or event. For treatment-outcome questions (e.g. immunotherapy response), say this first; the only proxies are `OS_MONTHS`/`OS_STATUS`, or NLP radiology progression events (`Diagnosis` events with `SUBTYPE = 'Progression'`, key `PROGRESSION` = Y/N/Indeterminate), in patients with `Treatment` events of the relevant `SUBTYPE` (e.g. `Immuno`: 3,341 patients). Hand off the comparison to cBioPortal group comparison / survival. **Nearly one sample per patient: 24,950 patients / 25,040 samples.** Only 90 patients have more than one sample, and all 90 have samples from two different cancer types (second primaries); only 26 have both a `Primary` and a `Metastasis` sample. There is no meaningful same-patient (paired) primary-vs-metastasis cohort. For "same patient" / paired questions, say this up front, then offer the **unpaired** comparison of all `Primary` vs `Metastasis` samples (`SAMPLE_TYPE`), labelled as unpaired. ```sql SELECT countIf(n > 1) AS multi_sample_patients, -- 90 countIf(has_p AND has_m) AS primary_and_met -- 26 FROM (SELECT patient_unique_id, count() AS n, has(groupArray(attribute_value), 'Primary') AS has_p, has(groupArray(attribute_value), 'Metastasis') AS has_m FROM clinical_data_derived WHERE cancer_study_identifier = 'msk_chord_2024' AND attribute_name = 'SAMPLE_TYPE' GROUP BY patient_unique_id); ``` ## Gene Panels This study uses multiple MSK-IMPACT panel versions: - **IMPACT341**: Earlier version, 341 genes - **IMPACT410**: 410 genes - **IMPACT468**: 468 genes - **IMPACT505**: Latest version, 505 genes **Important:** Different samples may have different gene coverage. Always use gene-specific denominators when calculating mutation frequencies. ## Clinical Attributes - Semantic Guide ### Cancer Classification | Attribute | Description | Values | |-----------|-------------|--------| | `CANCER_TYPE` | Broad cancer category | e.g., "Non-Small Cell Lung Cancer", "Breast Cancer" | | `CANCER_TYPE_DETAILED` | Specific subtype | e.g., "Lung Adenocarcinoma", "Invasive Ductal Carcinoma" | | `ONCOTREE_CODE` | OncoTree classification code | Standardized cancer type codes | ### Sample Information | Attribute | Description | Values | |-----------|-------------|--------| | `SAMPLE_TYPE` | Sample origin | Primary, Metastasis, Local Recurrence, Unknown | | `SAMPLE_CLASS` | Sample … (5439 more chars) ◀ result {"columns":[]} ▶ clickhouse_list_tables {} ◀ result {"tables":[{"name":"allele_specific_copy_number"},{"name":"alteration_driver_annotation"},{"name":"cancer_study"},{"name":"cancer_study_query_preferences"},{"name":"cancer_study_tags"},{"name":"cbioportal_sequence_state"},{"name":"clinical_attribute_counts"},{"name":"clinical_attribute_meta"},{"name":"clinical_data_derived"},{"name":"clinical_event"},{"name":"clinical_event_data"},{"name":"clinical_event_data_derived"},{"name":"clinical_event_derived"},{"name":"clinical_patient"},{"name":"clinical_sample"},{"name":"cna_event"},{"name":"cna_panel_gene_coverage"},{"name":"cna_wes_coverage"},{"name":"co_altered_genes_in_study"},{"name":"copy_number_seg"},{"name":"copy_number_seg_file"},{"name":"gene"},{"name":"gene_alias"},{"name":"gene_alteration_frequency_by_cancer_type"},{"name":"gene_cna_distribution_in_study"},{"name":"gene_mutation_frequency_by_cancer_type"},{"name":"gene_mutation_frequency_in_studies"},{"name":"gene_mutation_frequency_in_study"},{"name":"gene_mutation_variants_in_study"},{"name":"gene_pair_coexpression"},{"name":"gene_panel"},{"name":"gene_panel_list"},{"name":"gene_panel_to_gene_derived"},{"name":"generic_assay_data_derived"},{"name":"generic_assay_meta_derived"},{"name":"generic_assay_profile_entity_derived"},{"name":"generic_entity_properties"},{"name":"geneset"},{"name":"geneset_gene"},{"name":"geneset_hierarchy_leaf"},{"name":"geneset_hierarchy_node"},{"name":"genetic_alteration"},{"name":"genetic_alteration_derived"},{"name":"genetic_entity"},{"name":"genetic_profile"},{"name":"genetic_profile_link"},{"name":"genetic_profile_samples"},{"name":"genomic_event_derived"},{"name":"gistic"},{"name":"gistic_to_gene"},{"name":"info"},{"name":"mut_sig"},{"name":"mutation"},{"name":"mutation_count_by_keyword"},{"name":"mutation_derived"},{"name":"mutation_event"},{"name":"mutation_panel_gene_coverage"},{"name":"mutation_wes_coverage"},{"name":"patient"},{"name":"reference_genome"},{"name":"reference_genome_gene"},{"name":"resource_definition"},{"name":"resource_patient"},{"name":"resource_sample"},{"name":"resource_study"},{"name":"sample"},{"name":"sample_cna_event"},{"name":"sample_derived"},{"name":"sample_list"},{"name":"sample_list_list"},{"name":"sample_profile"},{"name":"sample_to_gene_panel_derived"},{"name":"structural_variant"},{"name":"sv_panel_gene_coverage"},{"name":"sv_wes_coverage"},{"name":"top_cna_genes_in_study"},{"name":"top_mutated_genes_in_cohort"},{"name":"top_mutated_genes_in_study"},{"name":"top_sv_genes_in_study"},{"name":"treatment_counts_in_study"},{"name":"treatment_regimens_in_study"},{"name":"type_of_cancer"}]} ▶ clickhouse_run_select_query { "query": "SELECT * FROM gene_mutation_frequency_in_study(study = 'msk_chord_2024', gene = 'TP53')" } ◀ result {"rows":[{"cancer_type":"Prostate Cancer","altered_samples":837,"profiled_samples":3211,"frequency_pct":26.1},{"cancer_type":"Breast Cancer","altered_samples":2138,"profiled_samples":5368,"frequency_pct":39.8},{"cancer_type":"Pancreatic Cancer","altered_samples":2076,"profiled_samples":3109,"frequency_pct":66.8},{"cancer_type":"Colorectal Cancer","altered_samples":4068,"profiled_samples":5543,"frequency_pct":73.4},{"cancer_type":"Non-Small Cell Lung Cancer","altered_samples":4005,"profiled_samples":7809,"frequency_pct":51.3}]} ▶ clickhouse_run_select_query { "query": " -- Get TP53-mutant patients (count each patient only once) WITH tp53_mutant AS ( SELECT DISTINCT patient_unique_id FROM genomic_event_derived WHERE cancer_study_identifier = 'msk_chord_2024' AND hugo_gene_symbol = 'TP53' AND variant_type = 'mutation' AND mutation_status != 'UNCALLED' AND off_panel = 0 ), -- Get all patients profiled for TP53 tp53_profiled AS ( SELECT DISTINCT c.patient_unique_id FROM sample_to_gene_panel_derived s JOIN clinical_data_derived c ON s.sample_unique_id = c.sample_unique_id WHERE s.cancer_study_identifier = 'msk_chord_2024' AND s.alteration_type = 'MUTATION_EXTENDED' AND c.attribute_name IN ('CANCER_TYPE') -- Just need one clinical attribute per patient ) SELECT (SELECT COUNT() FROM tp53_mutant) AS tp53_mutant_patients, (SELECT COUNT() FROM tp53_profiled) AS tp53_profiled_patients, ROUND((SELECT COUNT() FROM tp53_mutant) * 100.0 / (SELECT COUNT() FROM tp53_profiled), 1) AS frequency_pct ", "max_rows": 10 } ◀ result {"rows":[{"tp53_mutant_patients":13105,"tp53_profiled_patients":24950,"frequency_pct":52.5}]} ▶ resolve_and_route { "studyIds": [ "msk_chord_2024" ] } ◀ result {"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","sampleCount":25040,"studyViewUrl":"https://www.cbioportal.org/study?id=msk_chord_2024","metadata":{"clinicalAttributeIds":["ADRENAL_GLANDS","BONE","CANCER_TYPE","CANCER_TYPE_DETAILED","CLINICAL_GROUP","CLINICAL_SUMMARY","CNS_BRAIN","CURRENT_AGE_DEID","DIAGNOSIS_DESCRIPTION","ETHNICITY","FRACTION_GENOME_ALTERED","GENDER","GENE_PANEL","GLEASON_FIRST_REPORTED","GLEASON_HIGHEST_REPORTED","GLEASON_SAMPLE_LEVEL","HER2","HISTORY_OF_PDL1","HR","ICD_O_HISTOLOGY_DESCRIPTION","INTRA_ABDOMINAL","LIVER","LUNG","LYMPH_NODES","METASTATIC_SITE","MSI_COMMENT","MSI_SCORE","MSI_TYPE","MUTATION_COUNT","NUM_ICDO_DX","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER","PATHOLOGICAL_GROUP","PDL1_POSITIVE","PLEURA","PRIMARY_SITE","PRIOR_MED_TO_MSK","RACE","REPRODUCTIVE_ORGANS","SAMPLE_CLASS","SAMPLE_COUNT","SAMPLE_COVERAGE","SAMPLE_TYPE","SMOKING_PREDICTIONS_3_CLASSES","SOMATIC_STATUS","STAGE_HIGHEST_RECORDED","TMB_NONSYNONYMOUS","TUMOR_PURITY"],"molecularProfileIds":["msk_chord_2024_cna","msk_chord_2024_mutations","msk_chord_2024_structural_variants"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations"]}}]}} ▶ navigate_to_results_view { "studyIds": [ "msk_chord_2024" ], "genes": [ "TP53" ], "tab": "oncoprint" } ◀ result {"success":true,"message":"Navigating to https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53&case_set_id=msk_chord_2024_all","url":"https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53&case_set_id=msk_chord_2024_all","data":{"studyIds":["msk_chord_2024"],"studies":[{"studyId":"msk_chord_2024","name":"MSK-CHORD (MSK, Nature 2024)","sampleCount":25040}],"genes":["TP53"],"caseSetId":"msk_chord_2024_all","pageDescription":"Visual summary of alterations in queried genes across samples."}} ═ answer (success) ## Answer **52.5% of patients in the MSK-CHORD Study have at least one TP53 mutation.** **Details:** - **TP53-mutant patients:** 13,105 out of 24,950 profiled patients - **Counting unit:** Patient-level (each patient counted once, regardless of sample count) - **Profiled denominator:** 24,950 patients with at least one sample profiled for TP53 mutations ### Frequency by Cancer Type TP53 mutation frequency varies substantially across the five cancer types in MSK-CHORD: | Cancer Type | TP53-Mutant | Profiled | Frequency | |---|---|---|---| | Colorectal Cancer | 4,068 | 5,543 | **73.4%** | | Pancreatic Cancer | 2,076 | 3,109 | **66.8%** | | Non-Small Cell Lung Cancer | 4,005 | 7,809 | **51.3%** | | Breast Cancer | 2,138 | 5,368 | **39.8%** | | Prostate Cancer | 837 | 3,211 | **26.1%** | --- ### Explore the Data [View TP53 mutations in MSK-CHORD OncoPrint](https://www.cbioportal.org/results/oncoprint?cancer_study_list=msk_chord_2024&gene_list=TP53&case_set_id=msk_chord_2024_all) — See the complete alteration landscape, mutation types, and sample-level details. [Browse MSK-CHORD cohort overview](https://www.cbioportal.org/study?id=msk_chord_2024) — Filter by clinical attributes (stage, treatment, outcomes) to explore TP53-mutant subgroups.